MiNK Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

INKT$10.30-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MiNK Therapeutics, Inc.
Date: March 18, 2025	By:	/s/ Jennifer S. Buell, Ph.D.
		Jennifer S. Buell, Ph.D.
		President, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Garo H. Armen, Ph.D.
Name	Title	Date
/s/ Jennifer S. Buell, Ph.D.	President, Chief Executive Officer and Director	March 18, 2025
Jennifer S. Buell, Ph.D.	(Principal Executive Officer)
/s/ Christine M. Klaskin	Treasurer (Principal Financial Officer and Principal	March 18, 2025
Christine M. Klaskin	Accounting Officer)
/s/ Garo H. Armen, Ph.D.	Chairman of the Board of Directors	March 18, 2025
/s/ Peter Behner	Director	March 18, 2025
Peter Behner
/s/ Brian Corvese	Director	March 18, 2025
Brian Corvese
/s/ Robert Kadlec, M.D.	Director	March 18, 2025
Robert Kadlec, M.D.
/s/ Barbara Ryan	Director	March 18, 2025
Barbara Ryan
/s/ Ulf Wiinberg	Director	March 18, 2025
Ulf Wiinberg

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.